Oleksandr V. Vasylchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Oleksandr V. Vasylchenko has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Yurii S. Moroz
Enamine Ltd., Kyiv, Ukraine
4 shared publications - Darya Starosyla
SI “L. V. Hromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine
3 shared publications - Oleksandr O. Grygorenko
Enamine Ltd., Winston Churchill Street 78, Kyїv, Ukraine, 02094
3 shared publications Petro Borysko
Bienta/Enamine Ltd, Chervonotkatska Street 78, Kyiv, 02094, Ukraine
3 shared publications- Tetiana Trokhymchuk
SI “L. V. Hromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine
3 shared publications Andrey V. Bogolubsky
Enamine Ltd., Chervonotkatska Street 78, Kyiv 02094, Ukraine
2 shared publications
Latest Publications
- 1 October 2026
- Published by Research and Production Company Ecopharm, Ltd. in Preventive medicine. Theory and practice
- Vol. 1 (13) , 23-30
METHODS FOR DETERMINING THE MECHANISM OF TARGETED PROTEIN DEGRADATION
Summary. Targeted protein degradation (TPD) is a modern strategy for developing new therapeutic agents that requires not only detection of decreased target abundance but also stepwise validation of the compound’s mechanism of action. In this approach, the disappearance of the target protein is necessary but insufficient, because it does not by itself distinguish proteasomal degradation from inhibition of protein synthesis, loss of antibody epitope, toxicity, or altered protein solubility. Therefore, degrader analysis should rely on a hierarchy of methods that sequentially assess target protein abundance, selectivity and kinetics, compound binding to the target or E3 ligase, ternary complex formation, ubiquitination, and dependence of target loss on proteasomal clearance. This article summarizes methods used in degrader development and groups them by the measured parameter, type of experimental response, and mechanistic information provided by each method. Objective: to define a hierarchy of methods used to study protein degraders and to show which stage of the mechanism of action is assessed by each group of methods. Conclusions. Rational development of protein degraders cannot rely solely on the observed decrease in target protein abundance. Quantitative, biophysical, cellular, structural, and causal assays should be combined to confirm compound binding, formation of a productive E3-ligase complex, target ubiquitination, and proteasomedependent degradation. This stepwise evidentiary framework reduces the risk of false interpretation and supports more rational optimization of molecules. Keywords: targeted protein degradation, ternary complex, luminescence, fluorescence.
- 1 October 2026
- Published by Research and Production Company Ecopharm, Ltd. in Preventive medicine. Theory and practice
- Vol. 1 (13) , 23-30
METHODS FOR DETERMINING THE MECHANISM OF TARGETED PROTEIN DEGRADATION
Summary. Targeted protein degradation (TPD) is a modern strategy for developing new therapeutic agents that requires not only detection of decreased target abundance but also stepwise validation of the compound’s mechanism of action. In this approach, the disappearance of the target protein is necessary but insufficient, because it does not by itself distinguish proteasomal degradation from inhibition of protein synthesis, loss of antibody epitope, toxicity, or altered protein solubility. Therefore, degrader analysis should rely on a hierarchy of methods that sequentially assess target protein abundance, selectivity and kinetics, compound binding to the target or E3 ligase, ternary complex formation, ubiquitination, and dependence of target loss on proteasomal clearance. This article summarizes methods used in degrader development and groups them by the measured parameter, type of experimental response, and mechanistic information provided by each method. Objective: to define a hierarchy of methods used to study protein degraders and to show which stage of the mechanism of action is assessed by each group of methods. Conclusions. Rational development of protein degraders cannot rely solely on the observed decrease in target protein abundance. Quantitative, biophysical, cellular, structural, and causal assays should be combined to confirm compound binding, formation of a productive E3-ligase complex, target ubiquitination, and proteasomedependent degradation. This stepwise evidentiary framework reduces the risk of false interpretation and supports more rational optimization of molecules. Keywords: targeted protein degradation, ternary complex, luminescence, fluorescence.
- 15 June 2025
- Published by Research and Production Company Ecopharm, Ltd.
- p. 26-36
EPIDERMAL GROWTH FACTOR AND ITS RECEPTORS: THEIR ROLE IN TARGETED THERAPY OF TUMORS AND VIRAL DISEASES
Summary. Epidermal growth factor (EGF) and its receptors (HER/ErbB family) are essential regulators of cellular proliferation, survival, angiogenesis, and differentiation. Their dysregulation is central to the pathogenesis of various cancers and viral infections. This review analyzes the structure, ligand-binding, and dimerization of HER-1, HER-2, HER-3, and HER-4, and their downstream signaling pathways such as MAPK, PI3K, and PKC. HER-2 is emphasized as a pivotal oncogenic driver in breast, ovarian, gastric, and bladder carcinomas, where targeted therapeutics including trastuzumab, lapatinib, neratinib, and afatinib are clinically used. Resistance mechanisms and the role of heat shock protein inhibitors (e.g., ganetespib) in enhancing therapy are discussed. Additionally, EGFR-mediated pathways are shown to facilitate entry of viruses like hepatitis C and B, by exploiting host receptor complexes involving CD81 and claudin-1. The review further explores natural polyphenols (delphinidin, quercetin, EGCG) as novel EGFR/ErbB2 tyrosine kinase inhibitors with anticancer and antiviral potential. These findings underscore the multifaceted role of the EGFR/ErbB system as a target for innovative therapeutic strategies in oncology and virology. Keywords: epidermal growth factor, HER/ErbB receptors, tyrosine kinase inhibitors, targeted therapy, breast cancer, hepatitis C virus, flavonoids, EGFR inhibitors, virus entry.
- 15 June 2025
- Published by Research and Production Company Ecopharm, Ltd.
- p. 26-36
EPIDERMAL GROWTH FACTOR AND ITS RECEPTORS: THEIR ROLE IN TARGETED THERAPY OF TUMORS AND VIRAL DISEASES
Summary. Epidermal growth factor (EGF) and its receptors (HER/ErbB family) are essential regulators of cellular proliferation, survival, angiogenesis, and differentiation. Their dysregulation is central to the pathogenesis of various cancers and viral infections. This review analyzes the structure, ligand-binding, and dimerization of HER-1, HER-2, HER-3, and HER-4, and their downstream signaling pathways such as MAPK, PI3K, and PKC. HER-2 is emphasized as a pivotal oncogenic driver in breast, ovarian, gastric, and bladder carcinomas, where targeted therapeutics including trastuzumab, lapatinib, neratinib, and afatinib are clinically used. Resistance mechanisms and the role of heat shock protein inhibitors (e.g., ganetespib) in enhancing therapy are discussed. Additionally, EGFR-mediated pathways are shown to facilitate entry of viruses like hepatitis C and B, by exploiting host receptor complexes involving CD81 and claudin-1. The review further explores natural polyphenols (delphinidin, quercetin, EGCG) as novel EGFR/ErbB2 tyrosine kinase inhibitors with anticancer and antiviral potential. These findings underscore the multifaceted role of the EGFR/ErbB system as a target for innovative therapeutic strategies in oncology and virology. Keywords: epidermal growth factor, HER/ErbB receptors, tyrosine kinase inhibitors, targeted therapy, breast cancer, hepatitis C virus, flavonoids, EGFR inhibitors, virus entry.
- 15 December 2024
- Published by Research and Production Company Ecopharm, Ltd. in Preventive medicine. Theory and practice
- Vol. 4 (8) , 40-47
ENTEROVIRUSES AND THEIR SENSITIVITY TO FLAVONOIDS
The review highlights the current state of research on enteroviruses, in particular polioviruses, ECHO viruses, Coxsackie, and enterovirus type 71, which cause a significant number of human infectious diseases. The main aspects of their replication, pathogenesis, and molecular biological properties are discussed. Particular attention is paid to the prospects for the use of flavonoids as antiviral agents. The mechanisms of their action are analyzed, including the inhibition of proteases and blocking the interaction of viral components with cellular targets. The cytotoxicity and antiviral efficacy of a number of flavonoid compounds in model systems are considered. The review emphasizes the importance of searching for new natural substances and synthetic derivatives for the development of therapeutic agents against enterovirus infections, given the limitations of existing treatment options and the peculiarities of the mutagenicity of these viruses.
- 15 December 2024
- Published by Research and Production Company Ecopharm, Ltd. in Preventive medicine. Theory and practice
- Vol. 4 (8) , 40-47
ENTEROVIRUSES AND THEIR SENSITIVITY TO FLAVONOIDS
The review highlights the current state of research on enteroviruses, in particular polioviruses, ECHO viruses, Coxsackie, and enterovirus type 71, which cause a significant number of human infectious diseases. The main aspects of their replication, pathogenesis, and molecular biological properties are discussed. Particular attention is paid to the prospects for the use of flavonoids as antiviral agents. The mechanisms of their action are analyzed, including the inhibition of proteases and blocking the interaction of viral components with cellular targets. The cytotoxicity and antiviral efficacy of a number of flavonoid compounds in model systems are considered. The review emphasizes the importance of searching for new natural substances and synthetic derivatives for the development of therapeutic agents against enterovirus infections, given the limitations of existing treatment options and the peculiarities of the mutagenicity of these viruses.
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 165, 258-272
Pros and cons of virtual screening based on public “Big Data”: In silico mining for new bromodomain inhibitors
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 165, 258-272
Pros and cons of virtual screening based on public “Big Data”: In silico mining for new bromodomain inhibitors
- 24 October 2018
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 20 (11) , 672-680
(Chlorosulfonyl)benzenesulfonyl Fluorides—Versatile Building Blocks for Combinatorial Chemistry: Design, Synthesis and Evaluation of a Covalent Inhibitor Library
Multigram synthesis of (chlorosulfonyl)benzenesulfonyl fluorides is described. Selective modification of these building blocks at the sulfonyl chloride function under parallel synthesis conditions is achieved. It is shown that the reaction scope includes the use of (hetero)aromatic and electron-poor aliphatic amines (e.g. amino nitriles). Utility of the method is demonstrated by preparation of the sulfonyl fluoride library for potential use as covalent fragments, which is demonstrated by a combination of in silico and in vitro screening against trypsin as a model enzyme. As a result, several inhibitors were identified with activity on the par to that of the known inhibitor.
- 24 October 2018
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 20 (11) , 672-680
(Chlorosulfonyl)benzenesulfonyl Fluorides—Versatile Building Blocks for Combinatorial Chemistry: Design, Synthesis and Evaluation of a Covalent Inhibitor Library
Multigram synthesis of (chlorosulfonyl)benzenesulfonyl fluorides is described. Selective modification of these building blocks at the sulfonyl chloride function under parallel synthesis conditions is achieved. It is shown that the reaction scope includes the use of (hetero)aromatic and electron-poor aliphatic amines (e.g. amino nitriles). Utility of the method is demonstrated by preparation of the sulfonyl fluoride library for potential use as covalent fragments, which is demonstrated by a combination of in silico and in vitro screening against trypsin as a model enzyme. As a result, several inhibitors were identified with activity on the par to that of the known inhibitor.
- 1 July 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (12) , 3399-3405
Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors
- 1 July 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (12) , 3399-3405
Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors
- 27 December 2017
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 20 (1) , 35-43
An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200…350, cLogP –1…3) was prepared. The success rate of the method was analyzed as a function of physico-chemical parameters of the products, and it was found that the method can be considered as a tool for lead-oriented synthesis. A hydantoin-bearing submicromolar primary hit acting as an Aurora kinase A inhibitor was discovered with a combination of rational design, parallel synthesis using the procedures developed, in silico and in vitro screenings.
- 27 December 2017
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 20 (1) , 35-43
An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200…350, cLogP –1…3) was prepared. The success rate of the method was analyzed as a function of physico-chemical parameters of the products, and it was found that the method can be considered as a tool for lead-oriented synthesis. A hydantoin-bearing submicromolar primary hit acting as an Aurora kinase A inhibitor was discovered with a combination of rational design, parallel synthesis using the procedures developed, in silico and in vitro screenings.